Which GLP-1 Treatment Offers the Best Value for Your Goals?
Wegovy vs Ozempic vs Mounjaro: Understanding Your Switching Options
The decision to switch between Wegovy and Mounjaro often comes down to individual response, cost considerations, and availability. Wegovy contains semaglutide, a GLP-1 receptor agonist that has been specifically licensed for weight management in the UK. Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors, offering a dual mechanism approach. It's important to note that whilst Ozempic contains the same active ingredient as Wegovy (semaglutide), it is licensed exclusively for type 2 diabetes treatment, not weight management.
Many patients consider switching from Mounjaro to Wegovy due to cost differences or side effect profiles. Others move from considering Ozempic alternatives to properly licensed weight management treatments. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which option aligns best with your health goals and circumstances. The switching process requires careful dose consideration and prescriber guidance to ensure continuity of treatment.
Cost Comparison: Wegovy vs Mounjaro Pricing Breakdown
When evaluating Wegovy vs Ozempic vs Mounjaro costs, significant savings are often possible through strategic switching. Our Wegovy pricing starts at £79.99 for the 0.25mg starter dose (after FIRST40 discount for new customers), progressing to £209.99 for the 2.4mg maintenance dose. Private Mounjaro prescriptions can cost £150-300+ monthly at some clinics, making Wegovy a more economical long-term option for many patients. Our bundle options further enhance value - the Intro Duo (0.25mg & 0.5mg) costs £169.99, providing two months of starter treatment.
Returning customers benefit from our DOSE25 discount code, applied automatically at checkout to reach our competitive pricing structure. The Progress Trio bundle (0.5mg, 1mg & 1.7mg) at £369.99 offers three months of dose escalation, whilst our Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99. These structured pricing options make treatment planning more predictable compared to variable private clinic charges for Mounjaro alternatives.
Clinical Evidence: How Wegovy Compares in Weight Management Studies
In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks in the STEP 1 study (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent results across different patient populations, including those with type 2 diabetes who saw average reductions of 9.6%. These results were achieved through the same GLP-1 mechanism that makes Wegovy effective for appetite regulation.
Mounjaro's dual GIP/GLP-1 approach has shown promising results in its own trial programme, though direct comparisons between the medications aren't possible due to different study designs and patient populations. Both treatments require commitment to lifestyle changes for optimal effectiveness. Your prescriber can review which clinical profile might be more suitable based on your individual health history and treatment response to date.
Wegovy Mechanism: How This GLP-1 Treatment Supports Weight Management
Wegovy works as a GLP-1 receptor agonist, mimicking a natural hormone that your body produces after eating to signal fullness. This mechanism helps reduce appetite and promotes a feeling of satiety after smaller meals, potentially making it easier to maintain a reduced-calorie diet. The treatment may also help reduce food cravings by working on appetite centres in the brain, creating a more sustainable approach to portion control. Unlike some weight management approaches that focus purely on calorie restriction, Wegovy addresses the biological signals that drive eating behaviour. This hormonal approach, combined with diet and exercise modifications, creates the foundation for the weight management results seen in clinical studies. The once-weekly injection schedule also offers convenience compared to daily medications or frequent clinic visits.
Simple Switching Process: From Assessment to Delivery
Switching to Wegovy through EverydayMeds begins with our streamlined 3-minute online clinical assessment, where you can indicate your current treatment and reasons for considering a change. Our prescribers review switching requests with particular attention to dose equivalency and any previous side effects you may have experienced with other GLP-1 treatments. Standard prescriber review takes up to 3 working days, though our express service offers review within 24 hours for urgent switching needs. Once approved, your Wegovy is dispatched via next-day delivery using our temperature-controlled cold-chain system to maintain medication integrity. The entire process is designed to minimise treatment gaps, with clear dosing instructions provided for safe transition from your previous medication.
Storage and Practical Considerations for Wegovy vs Alternatives
Wegovy offers practical advantages in storage flexibility compared to some alternatives, remaining stable for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen system is pre-filled and requires no mixing or preparation, with clear dose markings and an automatic injection mechanism. Wegovy follows a mandatory dose escalation schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg for maintenance from week 17 onwards. This gradual increase helps minimise side effects whilst building towards the therapeutic dose proven effective in clinical trials. The once-weekly injection timing can be adjusted by up to 3 days if needed, offering flexibility around your schedule whilst maintaining consistent treatment levels.
Why Patients Switch: Wegovy vs Ozempic vs Mounjaro Decision Factors
The most common reasons patients switch between Wegovy and Mounjaro include cost considerations, side effect management, and treatment availability. Some patients find that Wegovy's GLP-1-only mechanism suits them better than Mounjaro's dual approach, particularly if they've experienced specific side effects with the latter. Others switch to Wegovy for the convenience of our bundle pricing structure and reliable UK supply chain through our GPhC-registered pharmacy (#9012878).
Cost sustainability often drives switching decisions, especially for maintenance treatment that may continue long-term. Wegovy's licensed indication specifically for weight management also provides confidence that you're using a treatment approved for your intended purpose. Our clinical team regularly assists patients transitioning between treatments, ensuring dose conversion is appropriate and monitoring requirements are maintained throughout the switching process.
Complete Your Switch to Wegovy Today
Ready to switch to Wegovy from Mounjaro or explore alternatives to Ozempic for weight management? Start with our clinical assessment at https://everydaymeds.co.uk/collections/weight-loss, where you can specify your current treatment and switching requirements. New customers automatically receive the FIRST40 discount at checkout, while returning customers benefit from DOSE25 savings. Our prescribers are experienced in GLP-1 treatment transitions and will ensure your switch is managed safely and effectively. Express review is available if you're approaching the end of your current supply. Don't let treatment gaps or cost concerns interrupt your weight management journey - EverydayMeds makes switching simple, safe, and affordable.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
